BOSTON (TheStreet) -- Arena Pharmaceuticals (ARNA) - Get Arena Pharmaceuticals, Inc. Report shares plunged Tuesday after a staff review of its experimental diet drug by the Food and Drug Administration highlighted three safety issues, including rat rumors and memory loss.
shares tumbled by $2.50, or 36.5%, to $4.35 after an initial review of its drug lorcaserin showed "valvular heart disease, neuro-psychiatric and cognitive-related adverse events, and preclinical tumor development" in rats.
The FDA staff review also noted that lorcaserin 10 mg tablet satisfied categorical efficacy criterion "by a slim margin." An FDA advisory panel will hold a public meeting on Thursday to discuss lorcaserin.
Other obesity drug makers were trading lower in sympathy.
, which saw an FDA panel vote against its drug Qnexa in July on safety risks, was down 1.1% to $6.07.
, which will meet with an FDA advisory panel in December over its drug Contrave, slumped nearly 7% to $4.79.
-- Written by Robert Holmes in Boston
>To contact the writer of this article, click here:
>To follow Robert Holmes on Twitter, go to
>To submit a news tip, send an email to:
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.